ArticleBMC psychiatry2026
Comparison of the effects of antipsychotic and combined with non-invasive brain stimulation on blood lipids in patients with schizophrenia.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
backgroundThis study aimed to compare the impact of antipsychotic treatment (APs) alone and a combination of antipsychotics and non-invasive brain stimulation (APNIBS) on blood lipid levels in patients with schizophrenia.
methodsA retrospective study was conducted. General demographic information and clinical and laboratory data, were collected from hospitalized patients who had received at least one lipid profile test after initiating therapy at the psychiatric hospital between January 2021 and October 2023. Lipid profiles, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C), were measured at baseline and multiple time points during treatment. The longitudinal changes in lipid profiles within each group (from baseline to each follow-up) and the differences in these trajectories between the two groups were assessed using linear mixed-effects models.
resultsA total of 1,171 patients were included (APs group: n = 704; APNIBS group: n = 467). At baseline, mean levels of TC, HDL-C, and LDL-C were within normal ranges, whereas TG was slightly elevated in the APs group. Linear mixed-effects model analysis revealed no statistically significant differences in the longitudinal trajectories of change between the two treatment groups for any lipid parameter (TG, TC, HDL-C, and LDL-C; all between-group P > 0.05). However, within-group analyses indicated divergent patterns: TG levels exhibited a progressive increase from baseline in the APs group at all follow-ups, while showing a more variable trajectory in the APNIBS group, with a increase at the second assessment after adjustment followed by decreasing trends later. Similarly, the APNIBS group demonstrated reductions from baseline in TC and LDL-C at the third and fourth tests, whereas no such reductions were observed in the APs group.
conclusionExploratory within-group analyses revealed favorable lipid trends in the APNIBS group. However, no statistically significant between-group differences were observed in longitudinal lipid trajectories. These hypothesis-generating findings warrant further prospective investigation into the potential role of NIBS in blood lipids management in schizophrenia. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.